CD36 is increasingly emerging as a favourable prognostic biomarker of tumour, primarily in epithelial origin tumours such as acute myeloid leukaemia, breast cancer, cervical cancer, colorectal cancer, gastric cancer, glioblastoma, hepatocellular carcinoma, oral squamous carcinoma, ovarian cancer, pancreatic cancer and prostate cancer (Table 1). Here, CD36 is linked to cervical cancer.